

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
28 December 2000 (28.12.2000)

PCT

(10) International Publication Number
WO 00/78973 A1

(51) International Patent Classification⁷: **C12N 15/53**,
C12P 7/22, C12N 9/02, A01K 67/033, A01H 5/00; A62D
3/00

(74) Agent: **ELLIS-JONES, Patrick, George, Armine; J.A.**
Kemp & Co., 14 South Square, Gray's Inn, London WC1R
5LX (GB).

(21) International Application Number: **PCT/GB00/02379**

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ,
DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,
HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ,
NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM,
TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(22) International Filing Date: **19 June 2000 (19.06.2000)**

(25) Filing Language: **English**

(26) Publication Language: **English**

(30) Priority Data:
9914373.7 **18 June 1999 (18.06.1999)** **GB**

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,
IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG,
CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

(71) Applicant (*for all designated States except US*): **ISIS IN-**
NOVATION LIMITED [GB/GB]; Ewert House, Ewert
Place, Summertown, Oxford OX2 7BZ (GB).

Published:

- *With international search report.*
- *Before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments.*

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **WONG, Luet, Lok**
[GB/GB]; University of Oxford, Dept. of Chemistry, South
Parks Road, Oxford OX1 3QR (GB). **JONES, Jonathan,**
Peter [GB/GB]; University of Oxford, Dept. of Chemistry,
South Parks Road, Oxford OX1 3QR (GB).

*For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.*

(54) Title: **PROCESS FOR OXIDISING AROMATIC COMPOUNDS**

(57) Abstract: Process for oxidising a substrate which is a halo aromatic compound, which process comprises oxidising said sub-
strate with a monooxygenase enzyme. The enzyme may be P450cam. The process may be carried out in cells, animals or plants.

WO 00/78973 A1

PROCESS FOR OXIDISING AROMATIC COMPOUNDS

The invention relates to a process for enzymatically oxidising halogenated aromatic compounds.

Chlorinated aromatic compounds such as the chlorobenzene and polychlorinated biphenyls (PCBs) are among the most wide-spread organic contaminants in the environment due to their common application as solvents, biocides, and in the heavy electrical industry. They are also some of the most problematic environmental pollutant, not only because of the health hazards (lipid solubility and hence accumulation in fatty tissues, toxicity and carcinogenicity) but also because of their slow degradation in the environment.

Whilst microorganisms have shown extraordinary abilities to adapt and evolve to degrade most of the organic chemicals released into the environment, the most chemically inert compounds such as PCBs do persist for two main reasons. First, these compounds have very low solubility in water and therefore their bioavailability is low. Research into this problem has focussed on the use of detergents and other surfactants to enhance their solubility and bioavailability. Second, these compounds require activation by enzymatic oxidation or reduction, and it can take a long time for the necessary genetic adaptations by microorganisms to occur, and even then the organisms may not be stable and viable.

We have now found, according to the present invention, that a monooxygenase, in particular P450_{cam} and its physiological electron transfer partners putidaretoxin and putidaretoxin reductase, can be used to oxidise halogenated aromatic compounds. Also mutants of the monooxygenase with substitutions in the active site have enhanced oxidation activity. Thus suitable monooxygenases can be expressed in microorganisms, animals and plants which are going to be used to oxidise the halogenated aromatic compounds.

Accordingly the present invention provides a process for oxidising a substrate which is a halo aromatic compound, which process comprises oxidising said substrate with a monooxygenase enzyme.


The process may be carried out in a cell that expresses:

- (a) the enzyme
- (b) an electron transfer reductase; and
- (c) an electron transfer redoxin.

The halo aromatic compound is typically a benzene or biphenyl compound. The benzene ring is optionally fused and can be substituted. The halogen is typically chlorine. In many cases there is more than one halogen atom in the molecule, typically 2 to 5 or 6, for example 3. Generally 2 of the halogen atoms will be ortho or para to one another. The compound may or may not contain an oxygen atom such as a hydroxy group, an aryloxy group or a carboxy group. The compound may or may not be chlorophenol or a chlorophenoxyacetic compound.

Specific compounds which can be oxidised by the process of the present invention include 1, 2; 1,3- and 1,4-dichlorobenzene, 1, 2, 4; 1, 2, 3- and 1, 3, 5-trichlorobenzene, 1, 2, 4, 5- and 1, 2, 3, 5- tetrachlorobenzene, pentachlorobenzene, hexachlorobenzene, 3,3'-dichlorobiphenyl and 2, 3, 4, 5, 6- and 2, 2', 4, 5, 5'-pentachlorobiphenyl.

Other compounds which can be oxidised by the process include recalcitrant halo aromatic compounds, especially dioxins and halogenated dibenzofurans, and the corresponding compounds where one or both oxygen atoms is/are replaced by sulphur, in particular compounds of the formula:



which possess at least one halo substituent, such as dioxin itself, 2,3,7,8-tetrachlorodibenzodioxin.

The oxidation typically gives rise to 1, 2 or more oxidation products. These oxidation products will generally comprise 1 or more hydroxyl groups. Generally, therefore, the oxidation products are phenols which can readily be degraded. It is particularly noteworthy that pentachlorobenzene and hexachlorobenzene can be oxidised in this way since they are very difficult to degrade. In contrast the corresponding phenols can be readily degraded by a variety of Pseudomonas and other bacteria. The atom which is oxidized is generally a ring carbon.

The enzyme is typically a natural monooxygenase or a mutant thereof. The

natural monooxygenase is generally a prokaryotic or eukaryotic enzyme. Typically it is a haem-containing enzyme and/or a P450 enzyme. The monooxygenase may or may not be a TfdA (2,4-dichlorophenoxy) acetate/ α -KG dioxygenase. The monooxygenase is generally of microorganism (e.g. bacterial), fungal, yeast, plant or animal origin, typically of a bacterium of the genus *Pseudomonas*. These organisms are typically soil, fresh water or salt water dwelling. In the case of a mutant monooxygenase the non-mutant form may or may not be able to oxidize the substrate.

The monooxygenase typically has a coupling efficiency of at least 1%, such as at least 2%, 4%, 6% or more. The monooxygenase typically has a product formation rate of at least 5 min⁻¹, such as at least 8, 10, 15, 20, 25, 50, 100, 150 min⁻¹ or more. The coupling efficiency or product formation rate is typically measured using any of the substrates or conditions mentioned herein. Thus they are typically measured in the in vitro conditions described in Example 2, in which case the relevant monooxygenase, reductase and redoxin would be present instead of, but at the same concentration as, P450_{cam}, putidaretoxin reductase and putidaretoxin.

The mutant typically has at least one mutation in the active site. A preferred mutant comprises a substitution of an amino acid in the active site by an amino acid with a less polar side chain. Thus the amino acid is typically substituted with an amino acid which is above it in Table 1.

Table 1. HYDROPATHY SCALE FOR AMINO ACID SIDE CHAINS

	Side Chain	Hydropathy
5		
	Ile	4.5
	Val	4.2
10	Leu	3.8
	Phe	2.8
	Cys	2.5
	Met	1.9
	Ala	1.8
15	Gly	-0.4
	Thr	-0.7
	Ser	-0.8
	Trp	-0.9
	Tyr	-1.3
20	Pro	-1.6
	His	-3.2
	Glu	-3.5
	Gln	-3.5
	Asp	-3.5
25	Asn	-3.5
	Lys	-3.9
	Arg	-4.5

30 An amino acid 'in the active site' is one which lines or defines the site in which the substrate is bound during catalysis or one which lines or defines a site through which the substrate must pass before reaching the catalytic site. Therefore such an amino acid typically interacts with the substrate during entry to the catalytic site or during catalysis. Such an interaction typically occurs through an electrostatic interaction (between charged or polar groups), hydrophobic interaction, hydrogen bonding or van der Waals forces.

35 The amino acids in the active site can be identified by routine methods to those skilled in the art. These methods include labelling studies in which the enzyme is allowed to bind a substrate which modifies ('labels') amino acids which contact the substrate. Alternatively the crystal structure of the enzyme with bound substrate can be obtained in order to deduce the amino acids in the active site.

The monooxygenase typically has 1, 2, 3, 4 or more other mutations, such as substitutions, insertions or deletions. The other mutations may be in the active site or outside the active site. Typically the mutations are in the 'second sphere' residues which affect or contact the position or orientation of one or more of the amino acids in the active site. The insertion is typically at the N and/or C terminal and thus the enzyme may be part of a fusion protein. The deletion typically comprises the deletion of amino acids which are not involved in catalysis, such as those outside the active site. The monooxygenase may thus comprise only those amino acids which are required for oxidation activity.

The other mutations in the active site typically alter the position and/or conformation of the substrate when it is bound in the active site. The mutation may make the site on the substrate which is to be oxidized more accessible to the haem group. Thus the mutation may be a substitution to an amino acid which has a smaller or larger, or more or less polar, side chain.

The other mutations typically increase the stability of the protein, or make it easier to purify the protein. They typically prevent the dimerisation of the protein, typically by removing cysteine residues from the protein (e.g. by substitution of cysteine at position 334 of P450_{cam}, or at an equivalent position in a homologue, preferably to alanine). They typically allow the protein to be prepared in soluble form, for example by the introduction of deletions or a poly-histidine tag, or by mutation of the N-terminal membrane anchoring sequence. The mutations typically inhibit protein oligomerisation, such as oligomerisation arising from contacts between hydrophobic patches on protein surfaces.

Typically the mutant monooxygenase is at least 70% homologous to a natural monooxygenase on the basis of amino acid identity.

Any of the homologous proteins mentioned herein are typically at least 70% homologous to a protein or at least 80 or 90% and more preferably at least 95%, 97% or 99% homologous thereto over at least 20, preferably at least 30, for instance at least 40, 60 or 100 or more contiguous amino acids. The contiguous amino acids may include the active site. This homology may alternatively be measured not over contiguous amino acids or nucleotides but over only the amino acids in the active site.

The monooxygenase is preferably:

(i) P450_{cam},

(ii) a naturally occurring homologue of (i),

(iii) a mutant of (i) or (ii).

Typically (i) is any allelic variant of P450_{cam} of *Pseudomonas putida* (e.g. of the polypeptide sequence shown in SEQ ID No. 1). Typically (ii) is a species homologue of (i) which has sequence homology with (i), and is typically P450_{BM-3} of *Bacillus megaterium* (e.g. the polypeptide sequence shown in SEQ ID No. 2), P450_{terp} of *Pseudomonas sp.*, P450_{eryF} of *Saccharopolyspora erythraea*, or P450 105 D1 (CYP105) of *Streptomyces griseus* strains.

The active site of (ii) or (iii) may be substantially the same as the active site of (i) or any of the mutants of (i) mentioned herein. Thus the site may comprise the same amino acids in substantially the same positions.

Typically in (iii) amino acid 96 of P450_{cam}, or the equivalent amino acid in a homologue, has been changed to an amino acid with a less polar side chain.

The 'equivalent' side chain in the homologue is one at the homologous position. This can be deduced by lining up the P450_{cam} sequence and the sequence of the homologue based on the homology between the two sequences. The PILEUP, BLAST and BESTFIT algorithms can be used to line up the sequences (for example as described in Altschul S. F. (1993) J Mol Evol 36:290-300; Altschul, S, F *et al* (1990) J Mol Biol 215:403-10 and (Devereux *et al* (1984) Nucleic Acids Research 12, p387-395)). These algorithms can also be used to calculate the levels of homology discussed herein (for example on their default settings). The equivalent amino acid will generally be in a similar place in the active site of the homologue as amino acid 96 in P450_{cam}.

The discussion below provides examples of the positions at which substitutions may be made in P450_{cam}. The same substitutions may be made at equivalent positions in the homologues. Standard nomenclature is used to denote the mutations. The letter of the amino acid present in the natural form is followed by the position, followed by the amino acid in the mutant. To denote multiple mutations in the same protein each mutation is listed separated by hyphens. The mutations discussed below using this nomenclature specify the natural amino acid in P450_{cam}, but it is to be understood that the mutation could be made to a homologue which has a different amino acid at the equivalent position. Note that the amino acid numbering shown in SEQ ID No. 1 for P450_{cam} does not correspond to the numbering used in the description to denote mutations. The numbering in SEQ ID No. 1 is one more than the numbering in the description for a particular position.

An additional mutation is typically an amino acid substitution at amino acid 87, 98, 101, 185, 244, 247, 248, 296, 395, 396 or a combination of these, for example as shown in table 2.

The following combinations of substitutions are preferred:

5 (i) Substitution at position 87 to amino acids of different side-chain volume, such as substitutions (typically of F) to A, L, I and W, combined with substitutions at position 96 to amino acids of different side-chain volume such as (typically Y to) A, L, F, and W. These combinations alter the space available in the upper part of the substrate pocket compared to the wild-type enzyme, for example, from Y96W-F87W (little space) to 10 Y96A-F87A (more space), as well as the location of the space, for example from one side in Y96F-F87A to the other in Y96A-F87W.

(ii) Substitution at position 96 to F combined with substitutions at positions 185 and 395. Both T185 and I395 are at the upper part of the substrate pocket, and substitution with A creates more space while substitution with F will reduce the space 15 available and push the substrate close to the haem.

(iii) Substitutions at position 96 to A, L, F, and W combined with substitutions at residues closer to the haem including at 101, 244, 247, 295, 296 and 396 to A, L, F, or W. These combinations will create or reduce space in the region of the different side-chains to offer different binding orientations to substrates of different sizes. For example, 20 the combinations Y96W-L244A and Y96L-V247W will offer very different pockets for the binding of the substrate.

(iv) Triple substitutions at combinations of positions 87, 96, 244, 247, 295, 296, 395 and 396 with combinations of A, L, F, and W. The aim is to vary the size and shape of the hydrophobic substrate binding pocket. For example, the Y96A-F87A-L244A 25 combination creates more space compared to the Y96F-F87W-V396L combination, thus allowing larger substrates to bind to the former while restricting the available binding orientations of smaller substrates in the latter. The combinations Y96F-F87W-V247L and Y96F-F87W-V295I have comparable substrate pocket volumes, but the locations of the space available for substrate binding are very different. The combination Y96F-F87L- 30 V247A has a slightly larger side-chain volume at the 96 position than the combination Y96L-F87L-V247A, but the L side-chain at the 96 position is much more flexible and the substrate binding orientations will be different for the two triple mutants.

(v) The mutants with four or five substitutions were designed with similar principles of manipulating the substrate volume, the different flexibility of various side-chains, and the location of the space available in the substrate pocket for substrate binding so as to effect changes in selectivity of substrate oxidation.

5 Mutations are generally introduced into the enzyme by using methods known in the art, such as site directed mutagenesis of the enzyme, PCR and gene shuffling methods or by the use of multiple mutagenic oligonucleotides in cycles of site-directed mutagenesis. Thus the mutations may be introduced in a directed or random manner. Typically the mutagenesis method produces one or more polynucleotides encoding one or more different
10 mutants. In one embodiment a library of mutant oligonucleotides is produced which can be used to produce a library of mutant enzymes.

The process is typically carried out in the presence of the natural cofactors of the monooxygenase. Thus typically in addition to the enzyme (a) and the substrate the process is carried out in the presence of an electron transfer reductase (b), an electron transfer
15 redoxin (c), cofactor for the enzyme and an oxygen donor. In this system the flow of electrons is generally: cofactor \rightarrow (b) \rightarrow (c) \rightarrow (a).

(b) is generally an electron transfer reductase which is able to mediate the transfer of electrons from the cofactor to (c), such as a naturally occurring reductase or a protein which has homology with a naturally occurring reductase, such as at least 70%
20 homology; or a fragment of the reductase or homologue. (b) is typically a reductase of any of the organisms mentioned herein, and is typically a flavin dependent reductase, such as putidaredoxin reductase.

(c) is generally an electron transfer redoxin which is able to mediate the transfer of electrons from the cofactor to (a) via (b). (c) is typically a naturally occurring electron transfer redoxin or a protein which has homology with a naturally occurring electron transfer redoxin, such as at least 70% homology; or a fragment of the redoxin or
25 homologue. (c) is typically a redoxin of any of the organisms mentioned herein. (c) is typically a two-iron/two sulphur redoxin, such as putidaredoxin.

The cofactor is any compound capable of donating an electron to (b), such as
30 NADH. The oxygen donor is any compound capable of donating oxygen to (a), such as dioxygen.

Typically (a), (b) and (c) are present as separate proteins; however they may be

present in the same fusion protein. Typically only two of them, preferably (b) and (c), are present in the fusion protein. Typically these components are contiguous in the fusion protein and there is no linker peptide present.

Alternatively a linker may be present between the components. The linker generally comprises amino acids that do not have bulky side chains and therefore do not obstruct the folding of the protein subunits. Preferably the amino acids in the linker are uncharged. Preferred amino acids in the linker are glycine, serine, alanine or threonine. In one embodiment the linker comprises the sequence N-Thr-Asp-Gly-Gly-Ser-Ser-Ser-C. The linker is typically from at least 5 amino acids long, such as at least 10, 30 or 50 or more amino acids long.

In the process the concentration of (a), (b) or (c) is typically from 10^{-8} to 10^{-2} M, preferably from 10^{-6} to 10^{-4} M. Typically the ratio of concentrations of (a): (b) and/or (a): (c) is from 0.1:0.1 to 1:10, preferably from 1:0.5 to 1:2, or from 1:0.8 to 1:1.2. Generally the process is carried out at a temperature and/or pH at which the enzyme is functional, such as when the enzyme has at least 20%, 50%, 80% or more of peak activity. Typically the pH is from 3 to 11, such as 5 to 9 or 6 to 8, preferably 7 to 7.8 or 7.4. Typically the temperature is 10 to 90°C, such as 25 to 75°C or 30 to 60°C.

In the process different monooxygenases may be present. Typically each of these will be able to oxidise different substrates, and thus using a mixture of monooxygenases will enable a wider range of substrates to be oxidised.

In one embodiment the process is carried out in the presence of a substance able to remove hydrogen peroxide by-product (e.g. a catalase).

In one embodiment the process is carried out in the presence of the enzyme, substrate and an oxygen atom donor, such as hydrogen peroxide or t-butylhydroperoxide, for example using the peroxide shunt.

In one embodiment in the process the (a), (b) and (c) together are typically in a substantially isolated form and/or a substantially purified form, in which case together they will generally comprise at least 90%, e.g., at least 95%, 98% or 99% of the protein in the preparation.

The process may be carried out inside or outside a cell. The cell is typically in culture, at a locus, in vivo or in planta (these aspects are discussed below).

The process is typically carried out at a locus such as in land (e.g. in soil) or in

water (e.g. fresh water or sea water). When it carried out in culture the culture typically comprises different types of cells of the invention, for example expressing different monooxygenases of the invention. Generally such cells are cultured in the presence of assimilable carbon and nitrogen sources.

5 Typically the cell in which the process is carried out is one in which the monooxygenase does not naturally occur. In another embodiment the monooxygenase is expressed in a cell in which it does naturally occur, but at higher levels than naturally occurring levels. The cell may produce 1, 2, 3, 4 or more different monooxygenases of the invention. These monooxygenases may be capable of oxidising different halo aromatic
10 compounds. Typically the cell also expresses any of the reductases and/or redoxins discussed above.

The cell is typically produced by introducing into a cell (i.e. transforming the cell with) a vector comprising a polynucleotide that encodes the monooxygenase. The vector may integrate into the genome of the cell or remain extrachromosomal. The cell may
15 develop into the animal or plant discussed below. Typically the coding sequence of the polynucleotide is operably linked to a control sequence which is capable of providing for the expression of the coding sequence by the host cell. The control sequence is generally a promoter, typically of the cell in which the monooxygenase expressed.

The term "operably linked" refers to a juxtaposition wherein the components
20 described are in a relationship permitting them to function in their intended manner. A control sequence "operably linked" to a coding sequence is ligated in such a way that expression of the coding sequence is achieved under conditions compatible with the control sequences.

The vector is typically a transposon, plasmid, virus or phage vector. It typically
25 comprises an origin of replication. It typically comprises one or more selectable marker genes, for example an ampicillin resistance gene in the case of a bacterial plasmid. The vector is typically introduced into host cells using conventional techniques including calcium phosphate precipitation, DEAE-dextran transfection, or electroporation.

Components (b) and (c) may be expressed in the cell in a similar manner.
30 Typically (a), (b) and (c) are expressed from the same vector, or may be expressed from different vectors. They may be expressed as three different polypeptides. Alternatively they may be expressed in the form of fusion proteins. The cell typically expresses more

than one type of monooxygenase.

In one embodiment the three genes encoding the three proteins of the P450_{cam} system, i.e. camA, camB, and camC are placed in the mobile regions of standard transposon vectors and incorporated into the genome of *Pseudomonas* and *flavobacteria*.
5 Alternatively plasmid vectors for expressing these genes may be used, in which case the P450_{cam} gene cluster will be extra-chromosomal.

The cell may be prokaryotic or eukaryotic and is generally any of the cells or of any of the organisms mentioned herein. Preferred cells are *Pseudomonas*, *flavobacteria* or fungi cells (e.g. *Aspergillus*). In one embodiment the cell is one which in its naturally
10 occurring form is able to oxidise any of the substrates mentioned herein. Typically the cell is in a substantially isolated form and/or substantially purified form, in which case it will generally comprise at least 90%, e.g. at least 95%, 98% or 99% of the cells or dry mass of the preparation.

The invention provides a transgenic animal or plant whose cells are any of the
15 cells of the invention. The animal or plant is transgenic for the monooxygenase gene and typically also an appropriate electron transfer reductase and/or redoxin gene. They may be homozygote or heterozygote for such genes, which are typically transiently introduced into the cells, or stably integrated (e.g. in the genome). The animal is typically a worm (e.g. earthworm) or nematode. The plant or animal may be obtained by transforming an
20 appropriate cell (e.g. embryo stem cell, callus or germ cell), fertilising the cell if required, allowing the cell to develop into the animal or plant and breeding the animal or plant true if required. The animal or plant may be obtained by sexual or asexual (e.g. cloning) propagation of an animal or plant of the invention or of the F1 organism (or any generation removed from the F1, or the chimera that develops from the transformed cell).

25 As discussed above the process may be carried out at a locus. Thus the invention also provides a method of treating a locus contaminated with a halo aromatic compound comprising contacting the locus with a monooxygenase, cell, animal or plant of the invention. These organisms are then typically allowed to oxidise the halo aromatic compound. In one embodiment the organisms used to treat the locus are native to the
30 locus. Thus they may be obtained from the locus (e.g. after contamination), transformed/transfected (as discussed above) to express the monooxygenase (and optionally an appropriate electron transfer reductase and/or redoxin).

In one embodiment the locus is treated with more than one type of organism of the invention, e.g. with 2, 3, 4, or more types which express different monooxygenases which oxidise different halo aromatic compounds. In one embodiment such a collection of organisms between them is able to oxidise all halobenzenes, e.g. all chlorobenzenes.

5 The organisms (e.g. in the form of the collection) may carry out the process of the invention in a bioreactor (e.g. in which they are present in immobilised form). Thus the water or soil to be treated may be passed through such a bioreactor. Soil may be washed with water augmented with surfactants or ethanol and then introduced into the bioreactor.

10 The invention also provides a process for selecting a mutant of a monooxygenase for its ability to oxidise any of the substrates mentioned herein, which process comprises screening a library of said mutants for their oxidation effect on the substrate. Thus typically the substrate is provided to the library and mutants are selected based on their ability to oxidise the substrate, for example at a particular rate or under particular conditions. The mutant may be selected based on its ability to oxidise the substrate to a
15 particular oxidation product.

 Typically the library will be in the form of cells which comprise the mutant enzymes. Generally each cell will express only one particular mutant enzyme. The library typically comprises at least 500 mutants, such as at least 1,000 or 5,000 mutants, preferably at least 10,000 different mutants.

20 The library typically comprises a random population of mutants. The library may undergo one or more rounds of selection whilst being produced and therefore may not comprise a random population.

 The library is typically produced by contacting any of the cells discussed herein which expresses the monooxygenase with a mutagen and/or when the cell is a mutator cell
25 culturing the cell in conditions in which mutants are produced. The mutagen may be contacted with the cell prior to or during culturing of the cell. Thus the mutagen may be present during replication of the cell or replication of the genome of the cell.

 The mutagen generally causes random mutations in the polynucleotide sequence which encodes (a). The mutagen is typically a chemical mutagen, such as
30 nitrosomethylguanidine, methyl- or ethylmethane sulphonic acid, nitrite, hydroxylamine, DNA base analogues, and acridine dyes, such as proflavin. It is typically electromagnetic radiation, such as ultra-violet radiation at 260 nm (absorption maximum of DNA) and X-

rays. It is typically ionising radiation.

A mutator cell is generally deficient in one or more of the primary DNA repair pathways (such as *E. Coli* pathways mutS, mutD or mutT, or their equivalents in another organism), and thus has a high mutation rate. Simply culturing such cell leads to the DNA encoding (a) to become mutated. The cell may be of *E. Coli* XL1 Red mutator strain.

The mutant selected from the library may be used in any aspect of the invention, thus it may be used to oxidise a substrate in the process of the invention or may be expressed in the cell, animal or plant of the invention. It may be used in the method of treating a locus.

The invention is also illustrated by the Examples:

Example 1

Expression of mutants for *in vitro* work.

The P450_{cam} enzymes were expressed using the vector pRH1091 (Baldwin, J.E., Blackburn, J.M., Heath, R.J., and Sutherland, J.D. *Bioorg. Med. Chem. Letts.*, 1992, 2, 663-668.) which utilised the *trc* promoter (a fusion of the *trp* and *lac* promoters). This vector incorporates a strong ribosome binding site (RBS) and the gene to be expressed is cloned using an *Nde* I site on the 5' end of the gene. We used *Hind* III as the cloning site at the 3' end of the *camC* gene. The procedure for protein expression is as follows: Cells are grown at 30°C until the OD_{600nm} reaches 1.0 – 1.2, the temperature is increased to 37°C and camphor added as a 1 M stock in ethanol to a final concentration of 1 mM. The culture is allowed to incubate at 37°C for another 6 hours. The P450_{cam} protein is expressed to high levels in the cytoplasm and the cells take on a red to orange-red colour.

We have also prepared a variant of pRH1091 (by PCR) which has an extra *Xba* I site between the RBS and the *Nde* I site. This is important because *Nde* I is not unique in M13, and this restriction site is also present in the reductase gene as well as the backbone of the pGLW11 vector used for the *in vivo* system. *Xba* I is unique in the polylinker region of M13, but absent in the genes of all three proteins in the P450_{cam} system and in the expression vectors. It therefore allows the *camC* gene to be moved between the mutagenic and expression vectors.

How the mutants were made.

Oligonucleotide-directed site-specific mutagenesis was carried out by the Kunkel method (Kunkel, T. A. *Proc. Natl. Acad. Sci. USA* 1985, 82, 488-492) using the Bio-Rad Mutagen kit. The recommended procedure is summarised as follows. An M13 mp19 subclone of the *camC* gene encoding P450_{cam} was propagated in the *E. coli* strain CJ236. This strain has the *dut*⁻*ung*⁻ phenotype and thus will tolerate the inclusion of uracil in place of thymine in DNA molecules. After three cycles of infection, uracil-containing single stranded (USS) M13 DNA was readily isolated by phenol extraction of mature M13 phage particles excreted into the growth medium. The mutagenic oligonucleotide (or oligonucleotides) were phosphorylated with T4 polynucleotide kinase and then annealed to the USS template. The four nucleotides, DNA polymerase, DNA ligase, ATP and other chemical components were added and the second strand was synthesised *in vitro*. The double stranded form thus obtained was transformed into the *dut*⁺*ung*⁺ *E. coli* strain MV1190, which should degrade the uracil-containing template strand and propagate the mutant strand synthesised *in vitro*. Plaques were picked and phages of possible mutants grown in *E. coli* strains MV1190 or TG1. The single-stranded DNA from these were sequenced to determine whether the mutagenesis reaction was successful. The mutagenic efficiency was 50 - 80%.

The mutant *camC* gene is excised from the M13 subclone by restriction digest with *Nde* I and *Hind* III, and the fragment of appropriate size is ligated to the backbone of the expression vector prepared by a similar *Nde* I/*Hind* III digest.

Multiple mutants were prepared either by further mutagenesis, also by the Kunkel method, or where the location of the sites in the sequence permits, simple cloning steps. There are two unique restriction sites within the *camC* gene which are absent from the expression vector. One is *Sph* I which spans residues 121 - 123, and the other is *Sal* I which spans residues 338 and 339. Therefore, all mutations at, for example, residues 87, 96, 98, and 101 are readily combined with mutations at higher number residues by ligating appropriate fragments from restriction digests of mutant *camC* genes with *Nde* I/*Sph* I and *Sph* I/*Hind* III and the backbone fragment from a *Nde* I/*Sph* I digest of the expression vector. Mutations at, for example, 395 and 396 can be similarly incorporated by digests in which *Sph* I is replaced with *Sal* I.

The rationale for introducing the unique *Xba* I site is now clear: many mutants with

multiple mutations were prepared by the cloning procedure above. Without the *Xba* I site it would be impossible to clone the gene for these multiple mutants from the expression vector back into M13 for further rounds of mutagenesis. Of course these problems could be overcome by doing mutagenesis by PCR, for example.

5 Example 2

Substrate oxidation protocol: *in vitro* reactions

Component	Final concentration
P450 _{cam} enzyme	1 μ M
Putidaredoxin	10 μ M
10 Putidaredoxin reductase	1 μ M
Bovine liver catalase	20 μ g/ml
KCl	200 mM
Substrate	Typically 1 mM
NADH	250 - 400 μ M

- 15 * 50 mM Tris-HCl buffer pH 7.4 is added to make up the volume.
 * Temperature controlled at 30°C, optional.
 * The NADH turnover rate could be determined by monitoring the absorbance at
 340 nm with time.
 * Catalase does not catalyse the substrate oxidation reactions but rather it is present
 20 to remove any hydrogen peroxide by-product which could otherwise denature the P450_{cam}.

The method can be increased in scale to, for example, 20 ml total incubation volume to allow purification of sufficient products by HPLC for spectroscopic characterisation. Fresh substrate (1 mM) and NADH (1 - 2 mM) are added periodically, such as every 20 minutes in a total reaction time of, typically, 3 hours.

25 Example 3

The *in vivo* system

The *in vivo* systems were expressed using the vector pGLW11, a derivative of the plasmid pKK223 (Brosius, J. and Holy, A. *Proc. Natl. Acad. Sci. USA*, 1984, **81**,6929-6933). Expression is directed by the *tac* promoter and the vector incorporates a gene

conferring resistance to the antibiotic ampicillin.

Two systems were constructed. The first one expressed the electron transfer proteins putidaredoxin reductase (*camA* gene) and putidaredoxin (*camB* gene) as a fusion protein with a seven amino acid peptide linker, and the P450_{cam} enzyme (*camC* gene) was expressed by the same vector but it was not fused to the electron proteins. The second system expressed the three proteins as separate entities in the *E. Coli* host. Both systems were catalytically competent for substrate oxidation *in vivo*.

The general strategy was as follows. The genes for the three proteins were cloned using *Eco* RI and *Hind* III as flanking sites, with *Eco* RI at the 5' end. For both *in vivo* systems there are restriction sites between the genes, including between the reductase and redoxin genes in the fusion construct. These restriction sites were introduced by PCR, as detailed below. The first task, however, was to carry out a silent mutation to remove the *Hind* III site within the *camA* gene for the reductase. The AAGCTT *Hind* III recognition sequence in the *camA* gene was changed to AAGCCT, which is a silent mutation because GCT and GCC both encode alanine. The gene was completely sequenced to ensure that there were no spurious mutations.

1. The fusion protein system

1.a Manipulation of the *camA* gene by PCR

For the *camA* gene the primer below was used at the 5' end of the gene to introduce the *Eco* RI cloning site and to change the first codon from GTG to the strong start codon ATG.

5'- GAG ATT AAG AAT TCA TAA ACA CAT GGG AGT GCG TGC CAT ATG AAC GCA AAC
 Eco RI RBS | -*camA*

At the 3' end of *camA* the primer was designed such that 15 bases are complementary to nucleotide sequence of the last five amino acid residues of *camA*. The stop codon immediately after the GCC codon for the last amino acid was removed, and then part of a seven amino acid linker (Thr Asp Gly Gly Ser Ser Ser) which contained a *Bam* HI cloning site (GGATCC = Gly Ser) was introduced. The coding sequence was thus:

-17-

5'- GAA CTG AGT AGT GCC ACT GAC GGA GGA TCC TCA TCG-3'

camA ~ Thr Asp Gly Gly Ser

|*Bam* HI|

5 The primer sequence shown below is the reverse complement used for PCR:

5'- CGA TGA GGA TCC TCC GTC AGT GGC ACT ACT CAG TTC-3'

1.b *Manipulations of the camB gene by PCR*

For the *camB* gene the primer at the 5' end incorporated the second half of the peptide linker between the reductase and redoxin proteins, and the restriction site *Bam* HI for joining the two amplified genes together.

5'- TCA TCG GGA TCC TCA TCG ATG TCT AAA GTA GTG TAT-3'

Gly Ser Ser Ser |~ *camB*

|*Bam* HI| Start

At the 3' end of *camB* the primer incorporates 12 nucleotides complementary to the end of *camB* followed by the stop codon TAA, a 6 nucleotide spacer before the GGAG ribosome binding site. *Xba* I and *Hind* III sites were then added to allow cloning of the *camC* gene when required. The sequence of the coding strand was therefore:

5'- CCC GAT AGG CAA TGG TAA TCA TCG GGAG TCT AGA GCA TCG AAG CTT TCA TCG-3'

CamB ~|stop RBS *Xba* I *Hind* III

20 The primer shown below is the reverse complement used for PCR:

5'-CGA TGA AAG CTT CGA TGC TCT AGA CTCC CGA TGA TTA CCA TTG CCT ATC GGG -3'

1.c *Preparation of the full fusion construct*

The *camA* and *camB* genes were amplified by the PCR using the primers described above. The new *camA* was digested with *Eco* RI and *Bam* HI, while the new *CamB* was digested with *Bam* HI and *Hind* III. The pGLW11 expression vector was digested with *Eco* RI and *Hind* III. All three were purified by agarose gel electrophoresis and the three gel slices containing the separate fragments were excised from the gel and ligated together, and then transformed into *E.Coli* DH5α. Successful ligation of all the fragments were

confirmed by a series of restriction digestion experiments, especially the presence of the new and unique *Xba* I site. The entire sequence of the insert from the *Eco* RI site to the *Hind* III site was determined to ensure that all the sequences were correct.

5 The new plasmid, named pSGB^F, was transformed into *E. Coli* and expression of the reductase and redoxin proteins was induced by IPTG. When a purified P450_{cam} enzyme was added to the cell-free extract, substrate oxidation was observed for a variety of substrates.

10 When the *camC* gene is cloned into the pSGB^F plasmid using the *Xba* I and *Hind* III restriction sites, the new recombinant plasmid thus generated expresses the reductase and redoxin as a fusion protein and the P450_{cam} enzyme as a separate entity both from the same mRNA molecule. This *in vivo* system is catalytically competent for terpene oxidation in whole cells.

2. The *in vivo* system with the protein expressed separately

2.a The basic strategy

15 The starting point of the preparation of this *in vivo* system was the recombinant plasmid used to express the *camA* gene for putidaredoxin reductase. The *camA* gene was cloned into the pGLW11 plasmid using the *Eco* RI and *Bam* HI restriction sites, with *Eco* RI being at the 5' end of the gene. Conveniently the polylinker region of the pGLW11 vector has a *Hind* III site downstream of the *Bam* HI site. The *camB* gene was therefore
20 manipulated by PCR such that it can be cloned into pGLW11 using the *Bam* HI and *Hind* III sites. This new plasmid expresses the reductase and redoxin as separate proteins.

The *camB* gene was cloned into pUC118 by the *Bam* HI and *Hind* III cloning sites to express putidaredoxin for our general *in vitro* substrate oxidation work. Therefore, the PCR primer at the 3' end of the *camB* gene was designed to introduce a ribosome binding
25 site and the *Xba* I restriction site upstream of the *Hind* III site so that the *camC* gene can be inserted downstream of *camB* using the *Xba* I and *Hind* III sites. Therefore the three genes were cloned without fusion in the pGLW11 expression vector and arranged in the order 5'-*camA-camB-camC*-3', and each gene has its own RBS to initiate protein synthesis.

2.b Manipulations of the *camB* gene

We used the internal and unique restriction site *Mlu* I (recognition sequence ACGCGT) within the *camB* gene as the starting point so that the PCR product has a different size from the PCR template fragment. The primers were as follows:

5 5'- TCA TCG **ACG CGT** CGC GAA CTG CTG-3'

where the *Mlu* I site is in bold.

The desired coding sequence at the 3' end of the *camB* gene was:

5'- CCC GAT AGG CAA TGG TAA GTA GGT GAA TAT CTA ATC CCC ATC

camB -|stop

10 TAT GCG CGA GTG **GAG TCT** AGA GTT CGA-3'

RBS *Xba* I

After the stop codon there is a 35 base spacer before the RBS which is used to initiate the synthesis of the P450_{cam} enzyme. The *Xba* I cloning site is located within the spacer between the RBS and the start codon (not in this primer) of the *camC* gene. The
 15 PCR primer used was the reverse complement of the sequence above. The PCR was carried out and the amplified fragment of the appropriate size was purified by agarose gel electrophoresis and the gel slice excised.

One extra step was necessary to complete the construction of the new plasmid. The plasmid for the fusion protein *in vivo* system was digested with *Mlu* I and *Hind* III
 20 restriction enzymes, purified by agarose gel electrophoresis, and the gel slice for the small *camB* fragment excised. The pUC118 plasmid for *camB* expression was similarly digested, and the gel slice for the backbone was excised. By ligating the two fragments together we prepared a new pUC118-based plasmid which had an *Xba* I site followed by an *Hind* III site downstream of the stop codon of *camB*. This new plasmid was digested with the *Mlu* I
 25 and *Xba* I enzymes and the backbone was ligated with the new *camB* fragment described above to generate a plasmid with the following arrangement of the key components:

..lac Promoter..Bam HI..camB gene..spacer..RBS..Xba I..Hind III..

2.c Preparation of the *in vivo* system plasmid

Once the modified *camB* with the *Xba* I and *Hind* III restriction sites and appropriate spacers were prepared, the *in vivo* system was constructed by cloning this into the pGLW11-based plasmid used to express the *camA* gene (reductase protein) using the *Bam* HI and *Hind* III sites. The new *in vivo* system vector has the following arrangement of the key components:

..tac Promoter..Eco IRI..RBS..camA gene..spacer..Bam HI..RBS..camB gene..spacer..RBS..Xba I.. Hind III..

This new plasmid, named pSGB⁺, was transformed into *E.Coli* and expression of the reductase and redoxin proteins was induced by IPTG. When a purified P450_{cam} enzyme was added to the cell-free extract, substrate oxidation was observed for a variety of substrates.

When the *camC* gene is cloned into this pSGC⁺ plasmid using the *Xba* I and *Hind* III restriction sites, the new recombinant plasmid thus generated will express the three proteins separately, each under the direction of its own RBS but from the same mRNA molecule. Thus constitutes the *in vivo* system used in the vast majority of our terpene oxidation work.

3. Introduction of an *Xba* I site into pRH1091

This is the final step to enable the *camC* gene to be cloned into the *in vivo* systems by the two cloning sites *Xba*I and *Hind* III. The *Xba* I site was added by PCR of the entire pRH1091 plasmid using two primers. The presence of these two sites will also enable cloning of the *camC* gene into M13 since both *Xba* I and *Hind* III are unique in *camC* and M13.

The primers shown below maintain the *Hind* III cloning site AAGCTT:

5'-TCA TCG AAG CTT GGC TGT TTT-3'

Hind III |→ vector

-21-

At the other end the coding sequence desired was:

5'-ACA ATT TCA CAC AGGA TCT AGA C CAT ATG TCA TCG AAG CTT TCA TCG-3'

Vector -|RBS *Xba* I *Nde* I *Hind* III

This sequence maintained the *Nde* I and *Hind* III sites but the new *Xba* I site was introduced upstream of the *Nde* I site. The PCR primer used was the reverse complement of the desired sequence:

5'-CGA TGA AAG CTT CGA TGA CAT ATG GTC T AGA TCCT GTG TGA AAT TGT-3'

The PCR product was then purified by agarose gel electrophoresis, digested with *Hind* III and circularised with T4 DNA ligase. Success of the PCR method was indicated by the presence of a new and unique *Xba* I site in plasmid DNA isolated from transformants.

4. Cloning of *camC* into the *in vivo* systems

All existing *camC* mutants were cut out of pRH1091-based expression plasmids with *Nde* I and *Hind* III. The new vector is similarly cut with the same restriction enzymes and the *camC* gene cloned into this plasmid with T4 DNA ligase. This DNA is transformed into *E. Coli* JM109 which then may be grown to express P450_{cam}.

The *camC* gene is excised from the new vector using *Xba* I and *Hind* III restriction enzymes and cloned into either the *in vivo* vector systems or M13mp19 for mutagenesis.

5. *In vivo* expression and substrate turnover

For protein expression, cells are grown in LBamp medium (tryptone 10 g/litre, yeast extract 5 g/litre, NaCl 10 g/litre, 50 µg/ml ampicillin) at 30°C until the OD_{600nm} reaches 1.0 - 1.2. IPTG (isopropyl-β-D-thiogalactopyranoside) was added to a final concentration of 1 µM (from a 1 M stock in H₂O) and the culture was incubated at 30°C overnight.

For simple screening the substrate can be added to culture and the incubation continued. However, due to impurities from the culture media the cells were generally washed twice with 0.5 vol. of buffer P, (KH₂PO₄ 6.4 g, K₂HPO₄·3H₂O 25.8 g, H₂O to 4

litres, pH 7.4) and resuspended in 0.25 vol. oxygen saturated buffer P containing 24 mM glucose. Substrate was added to 1 mM and the incubation continued at 30°C. The reaction was allowed to run for 24 hours with periodic additions of substrate and glucose.

Example 4

5 The oxidation of halo aromatic compounds

Mutant	2,3,6- Trichlorophenol	3,4,6- Trichlorophenol	Coupling Efficiency (%)	Product formation rate (min ⁻¹)
Y96F	75	25	18	22
Y96A	77	23	14	33
Y96H	54	46	3	1
10 F87L-Y96F	42	58	4	8
F87A-Y96F	52	48	2	3
F87A-Y96-F-V247A	43	57	4	7

Mutant	2,3- Dichlorophenol	3,4- Dichlorophenol	Coupling Efficiency (%)	Product formation rate (min ⁻¹)
Y96A	94	6	6	19
15 Y96F	91	9	4	8
Y96A-V247L	94	6	7	20
Y96L-V247A	90	10	2	0.7
F87L-96F	96	4	3	5
C334A	95	5	2	0.5

20 All mutants have C334A. Coupling efficiency is the percentage of NADH consumed which was utilised for product formation, i.e. a percentage of the theoretical maximum efficiency. The product formation rates are given in (nmol product) (nmol P450_{cam})⁻¹ (min)⁻¹. The relative amount of product formed in each case is shown.

1,3- and 1,4-dichlorobenzene, 1, 2, 3- and 1, 3, 5-trichlorobenzene, 1, 2, 4, 5- and 1, 2, 3, 5-tetrachlorobenzene, and 2, 3, 4, 5, 6- and 2, 2', 4, 5, 5'- pentachlorobiphenyl were also found to be oxidised.

Wild-type and mutant P450_{cam} enzymes were tested for their ability to oxidise 3,3'-dichlorobiphenyl and 2,2',4,5,5'-pentachlorobiphenyl. Results are shown in terms of NADH turnover. Rates are given as nanomol NADH consumed per nanomol P450_{cam} enzyme per minute.

P450 _{cam} enzyme	3,3'- dichlorobiphenyl	2,2',4,5,5'- pentachlorobiphenyl
Wild-type	0.4	not detected
Y96F	15	1
F87A-Y96F	845	165
F87L-Y96F	174	13
F87W-Y96F	4	3
F87A-Y96F-V247A	112	12
Y96A-V247L	84	37
F87A-Y96F-L244A	669	321
F87A-Y97F-L244A-V247A	173	214

The first product, 4-hydroxy-3,3'-dichlorobiphenyl was identified by the characteristic coupling patterns expected in the ¹H NMR spectrum and by mass spectroscopy. The further oxidation product, 4,4'-dihydroxy-3,3'-dichlorobiphenyl was identified by co-elution with an authentic sample, and by UV-vis and mass spectroscopy. This product did not constitute more than ca. 10% of the total products in any of the mutants tested.

For the second substrate product was established as 4'-hydroxy-2,2',4,5,5'-pentachlorobiphenyl by the observation of the parent ion in the mass spectrum, and by comparison with literature ¹H NMR data.

-24-

P450_{can} mutants

All mutants optionally contain the base mutation C334A.

Single mutants: Y96A, Y96F, Y96L, Y96W.

Double mutants:

Y96A-F87A	Y96F-F87A	Y96F-V295A	Y96L-F87A	Y96L-A296L
Y96A-F87L	Y96F-F87I	Y96F-V295L	Y96L-F87L	Y96L-A296F
Y96A-F87W	Y96F-F87L	Y96F-V295I	Y96L-F98W	Y96L-V396A
Y96A-F98W	Y96F-F87W	Y96F-A296L	Y96L-T101L	Y96L-V396L
Y96A-L244A	Y96F-F98W	Y96F-A296F	Y96L-T101F	Y96L-V396F
Y96A-V247A	Y96F-T101L	Y96F-I395F	Y96L-L244A	Y96L-V396W
Y96A-V247L	Y96F-T101F	Y96F-I395G	Y96L-L244F	
Y96A-I395F	Y96F-T185A	Y96F-V396A	Y96L-V247A	
Y96A-I395G	Y96F-T185F	Y96F-V396L	Y96L-V247L	Y96W-F87W
	Y96F-T185L	Y96F-V396F	Y96L-V247F	Y96W-F98W
	Y96F-L244A	Y96F-V396W	Y96L-V247W	Y96W-L244A
	Y96F-V247A		Y96L-G248L	Y96W-V247A
	Y96F-V247L		Y96L-V295L	Y96W-V396A
	Y96F-G248L		Y96L-V295F	

Triple Mutants:

Y96A-F87A-L244A	Y96L-V247A-V396L	Y96F-F87W-V247A
Y96A-F87A-V247A	Y96L-V247A-V396F	Y96F-F87W-V247L
Y96A-F87L-L244A	Y96L-V247A-V396W	Y96F-F87W-V247F
Y96A-F87L-V247A	Y96L-V247F-V396A	Y96F-F87W-V295L
Y96A-L244A-V247A		Y96F-F87W-A296L
	Y96F-F87A-L244A	Y96F-F87W-V396A
Y96L-F87A-L244A	Y96F-F87A-V247A	Y96F-F87W-V396L
Y96L-F87A-V247A	Y96F-F87A-V247L	Y96F-V247F-V396A
Y96L-F87L-L244A	Y96F-F87A-I395F	Y96F-L244A-V396L
Y96L-F87L-V247A	Y96F-F87A-I395G	Y96F-L244A-V396F
Y96L-V247A-I395F	Y96F-F87L-V247A	Y96F-L244A-V396W
Y96L-V247L-I395F	Y96F-F87L-V247L	Y96F-L244F-V396A
Y96L-V247L-I395G	Y96F-F87L-I395F	Y96F-V247A-V396L
Y96L-L244A-V396L	Y96F-F87W-T185A	Y96F-V247A-V396F
Y96L-L244A-V396F	Y96F-F87W-T185F	Y96F-V247A-V396W
Y96L-L244A-V396W	Y96F-F87W-T185L	
Y96L-L244F-V396A	Y96F-F87W-L244F	Y96W-F87W-F98W

Four mutations:

Y96A-F87A-L244A-V247A
Y96A-F87L-L244A-V247A
Y96L-F87A-L244A-V247A
Y96L-F87L-L244A-V247A

Five mutations:

Y96F-F87W-T185L-V247L-V295L
Y96F-F87W-T185L-V247L-V396A
Y96F-F87W-T185L-V247L-V396L

Y96F-F87W-L244A-V295L
Y96F-F87W-L244F-V396A
Y96F-F87W-L244A-A296L
Y96F-F87W-V247A-V396L
Y96F-F87W-V247A-V396F
Y96F-F87W-V247L-V295A
Y96F-F87W-V247L-V396A
Y96F-F87W-V247F-V396A
Y96F-F87W-V247A-I395F
Y96F-F87W-V247L-I395G

Table 2 (continued)

CLAIMS

1. Process for oxidising a substrate which is a halo aromatic compound, which process comprises oxidising said substrate with a monooxygenase enzyme.

2. Process according to claim 1 in which the enzyme comprises a substitution of an amino acid in the active site by an amino acid with a less polar side-chain.

3. Process according to claim 2 in which the enzyme comprises one or more other amino acid substitutions in the active site.

4. Process according to any one of the preceding claims in which the enzyme is

(i) P450_{cam}, or

(ii) a naturally occurring homologue of (i), or

(iii) a mutant of (i) or (ii).

5. Process according to claim 4 in which the enzyme is one in which amino acid 96 of P450_{cam}, or the equivalent amino acid in a homologue, has been changed to an amino acid with a less polar side-chain.

6. Process according to any one of the preceding claims in which the halogen is chlorine.

7. Process according to any one of the preceding claims in which the aromatic compound is a benzene or biphenyl.

8. Process according to any one of the preceding claims in which the substrate has more than one halogen atom.

9. Process according to claim 8 in which the substrate is 1, 2-dichlorobenzene, 1, 2, 4- trichlorobenzene, 3,3'-dichlorobiphenyl or 2,2',4,5,5'-pentachlorobiphenyl.

10. Process according to claim 8 in which the substrate is pentachlorobenzene or hexachlorobenzene.

11. Process according to any one of the preceding claims which is carried out in a cell that expresses:

(a) an enzyme as defined in any one of claims 1 to 5;

(b) an electron transfer reductase; and

(c) an electron transfer redoxin.

12. Process according to claim 11 in which:

(b) is putidaretoxin reductase or a homologue; or a fragment thereof; and/or

-27-

(c) is putidaretoxin or a homologue; or a fragment thereof.

13. Process according to claim 11 or 12 wherein the cell is one in which the enzyme (a) does not naturally occur.

5 14. Process according to any one of claims 11 to 13 wherein the cell is one which in its naturally occurring form is able to oxidise a substrate as defined in any one of claims 6 to 10.

15. A cell as defined in claim 14.

16. A transgenic animal or plant whose cells are as defined in any one of claims 11 to 14.

10 17. Method of treating a locus contaminated with a substrate as defined in any one of claims 1 or 6 to 10 comprising contacting the locus with an enzyme as defined in any one of claims 1 to 5 or a cell as defined in any of claims 11 to 13, or an animal or plant as defined in claim 16.

15 18. Process for selecting a mutant of an enzyme as defined in claim 1, 4(i) or 4(ii) for its ability to oxidise a substrate as defined in claim 1, or any one of the claims 6 to 10, which process comprises screening a library of said mutants for their oxidation effect on the substrate.

19. Process, cell, animal, plant or method according to any one of claims 1 to 17 wherein the enzyme is one that has been selected in a process according to claim 18.

-1-

SEQUENCE LISTING

<110> Isis Innovation Limited

<120> Process for oxidising aromatic compounds

<130> N76277A PEJ

5 <170> PatentIn Ver. 2.1

<210> 1

<211> 1242

<212> DNA

<213> Pseudomonas putida

10 <220>

<221> CDS

<222> (1)..(1242)

<400> 1

15 acg act gaa acc ata caa agc aac gcc aat ctt gcc cct ctg cca ccc 48
 Thr Thr Glu Thr Ile Gln Ser Asn Ala Asn Leu Ala Pro Leu Pro Pro
 1 5 10 15

cat gtg cca gag cac ctg gta ttc gac ttc gac atg tac aat ccg tcg 96
 His Val Pro Glu His Leu Val Phe Asp Phe Asp Met Tyr Asn Pro Ser
 20 25 30

20 aat ctg tct gcc ggc gtg cag gag gcc tgg gca gtt ctg caa gaa tca 144
 Asn Leu Ser Ala Gly Val Gln Glu Ala Trp Ala Val Leu Gln Glu Ser
 35 40 45

25 aac gta ccg gat ctg gtg tgg act cgc tgc aac ggc gga cac tgg atc 192
 Asn Val Pro Asp Leu Val Trp Thr Arg Cys Asn Gly Gly His Trp Ile
 50 55 60

gcc act cgc ggc caa ctg atc cgt gag gcc tat gaa gat tac cgc cac 240
 Ala Thr Arg Gly Gln Leu Ile Arg Glu Ala Tyr Glu Asp Tyr Arg His
 65 70 75 80

30 ttt tcc agc gag tgc ccg ttc atc cct cgt gaa gcc ggc gaa gcc tac 288
 Phe Ser Ser Glu Cys Pro Phe Ile Pro Arg Glu Ala Gly Glu Ala Tyr
 85 90 95

-2-

	gac ttc att ccc acc tcg atg gat ccg ccc gag cag cgc cag ttt cgt	336
	Asp Phe Ile Pro Thr Ser Met Asp Pro Pro Glu Gln Arg Gln Phe Arg	
	100 105 110	
5	gcg ctg gcc aac caa gtg gtt ggc atg ccg gtg gtg gat aag ctg gag	384
	Ala Leu Ala Asn Gln Val Val Gly Met Pro Val Val Asp Lys Leu Glu	
	115 120 125	
	aac cgg atc cag gag ctg gcc tgc tcg ctg atc gag agc ctg cgc ccg	432
	Asn Arg Ile Gln Glu Leu Ala Cys Ser Leu Ile Glu Ser Leu Arg Pro	
	130 135 140	
10	caa gga cag tgc aac ttc acc gag gac tac gcc gaa ccc ttc ccg ata	480
	Gln Gly Gln Cys Asn Phe Thr Glu Asp Tyr Ala Glu Pro Phe Pro Ile	
	145 150 155 160	
	cgc atc ttc atg ctg ctc gca ggt cta ccg gaa gaa gat atc ccg cac	528
	Arg Ile Phe Met Leu Leu Ala Gly Leu Pro Glu Glu Asp Ile Pro His	
15	165 170 175	
	ttg aaa tac cta acg gat cag atg acc cgt ccg gat ggc agc atg acc	576
	Leu Lys Tyr Leu Thr Asp Gln Met Thr Arg Pro Asp Gly Ser Met Thr	
	180 185 190	
20	ttc gca gag gcc aag gag gcg ctc tac gac tat ctg ata ccg atc atc	624
	Phe Ala Glu Ala Lys Glu Ala Leu Tyr Asp Tyr Leu Ile Pro Ile Ile	
	195 200 205	
	gag caa cgc agg cag aag ccg gga acc gac gct atc agc atc gtt gcc	672
	Glu Gln Arg Arg Gln Lys Pro Gly Thr Asp Ala Ile Ser Ile Val Ala	
	210 215 220	
25	aac ggc cag gtc aat ggg cga ccg atc acc agt gac gaa gcc aag agg	720
	Asn Gly Gln Val Asn Gly Arg Pro Ile Thr Ser Asp Glu Ala Lys Arg	
	225 230 235 240	

-3-

	atg tgt ggc ctg tta ctg gtc ggc ggc ctg gat acg gtg gtc aat ttc	768
	Met Cys Gly Leu Leu Leu Val Gly Gly Leu Asp Thr Val Val Asn Phe	
	245 250 255	
5	ctc agc ttc agc atg gag ttc ctg gcc aaa agc ccg gag cat cgc cag	816
	Leu Ser Phe Ser Met Glu Phe Leu Ala Lys Ser Pro Glu His Arg Gln	
	260 265 270	
	gag ctg atc gag cgt ccc gag cgt att cca gcc gct tgc gag gaa cta	864
	Glu Leu Ile Glu Arg Pro Glu Arg Ile Pro Ala Ala Cys Glu Glu Leu	
	275 280 285	
10	ctc cgg cgc ttc tcg ctg gtt gcc gat ggc cgc atc ctc acc tcc gat	912
	Leu Arg Arg Phe Ser Leu Val Ala Asp Gly Arg Ile Leu Thr Ser Asp	
	290 295 300	
	tac gag ttt cat ggc gtg caa ctg aag aaa ggt gac cag atc ctg cta	960
	Tyr Glu Phe His Gly Val Gln Leu Lys Lys Gly Asp Gln Ile Leu Leu	
15	305 310 315 320	
	ccg cag atg ctg tct ggc ctg gat gag cgc gaa aac gcc tgc ccg atg	1008
	Pro Gln Met Leu Ser Gly Leu Asp Glu Arg Glu Asn Ala Cys Pro Met	
	325 330 335	
20	cac gtc gac ttc agt cgc caa aag gtt tca cac acc acc ttt ggc cac	1056
	His Val Asp Phe Ser Arg Gln Lys Val Ser His Thr Thr Phe Gly His	
	340 345 350	
	ggc agc cat ctg tgc ctt ggc cag cac ctg gcc cgc cgg gaa atc atc	1104
	Gly Ser His Leu Cys Leu Gly Gln His Leu Ala Arg Arg Glu Ile Ile	
	355 360 365	
25	gtc acc ctc aag gaa tgg ctg acc agg att cct gac ttc tcc att gcc	1152
	Val Thr Leu Lys Glu Trp Leu Thr Arg Ile Pro Asp Phe Ser Ile Ala	
	370 375 380	

-4-

ccg ggt gcc cag att cag cac aag agc ggc atc gtc agc ggc gtg cag 1200
 Pro Gly Ala Gln Ile Gln His Lys Ser Gly Ile Val Ser Gly Val Gln
 385 390 395 400

5 gca ctc cct ctg gtc tgg gat ccg gcg act acc aaa gcg gta 1242
 Ala Leu Pro Leu Val Trp Asp Pro Ala Thr Thr Lys Ala Val
 405 410

<210> 2

<211> 3150

<212> DNA

10 <213> Bacillus megaterium

<220>

<221> CDS

<222> (1)..(3150)

<400> 2

15 atg aca att aaa gaa atg cct cag cca aaa acg ttt gga gag ctt aaa 48
 Met Thr Ile Lys Glu Met Pro Gln Pro Lys Thr Phe Gly Glu Leu Lys
 1 5 10 15

20 aat tta ccg tta tta aac aca gat aaa ccg gtt caa gct ttg atg aaa 96
 Asn Leu Pro Leu Leu Asn Thr Asp Lys Pro Val Gln Ala Leu Met Lys
 20 25 30

att gcg gat gaa tta gga gaa atc ttt aaa ttc gag gcg cct ggt cgt 144
 Ile Ala Asp Glu Leu Gly Glu Ile Phe Lys Phe Glu Ala Pro Gly Arg
 35 40 45

25 gta acg cgc tac tta tca agt cag cgt cta att aaa gaa gca tgc gat 192
 Val Thr Arg Tyr Leu Ser Ser Gln Arg Leu Ile Lys Glu Ala Cys Asp
 50 55 60

gaa tca cgc ttt gat aaa aac tta agt caa gcg ctt aaa ttt gta cgt 240
 Glu Ser Arg Phe Asp Lys Asn Leu Ser Gln Ala Leu Lys Phe Val Arg
 65 70 75 80

-5-

	gat ttt gca gga gac ggg tta ttt aca agc tgg acg cat gaa aaa aat	288
	Asp Phe Ala Gly Asp Gly Leu Phe Thr Ser Trp Thr His Glu Lys Asn	
	85 90 95	
5	tgg aaa aaa gcg cat aat atc tta ctt cca agc ttc agt cag cag gca	336
	Trp Lys Lys Ala His Asn Ile Leu Leu Pro Ser Phe Ser Gln Gln Ala	
	100 105 110	
	atg aaa ggc tat cat gcg atg atg gtc gat atc gcc gtg cag ctt gtt	384
	Met Lys Gly Tyr His Ala Met Met Val Asp Ile Ala Val Gln Leu Val	
	115 120 125	
10	caa aag tgg gag cgt cta aat gca gat gag cat att gaa gta ccg gaa	432
	Gln Lys Trp Glu Arg Leu Asn Ala Asp Glu His Ile Glu Val Pro Glu	
	130 135 140	
	gac atg aca cgt tta acg ctt gat aca att ggt ctt tgc ggc ttt aac	480
	Asp Met Thr Arg Leu Thr Leu Asp Thr Ile Gly Leu Cys Gly Phe Asn	
15	145 150 155 160	
	tat cgc ttt aac agc ttt tac cga gat cag cct cat cca ttt att aca	528
	Tyr Arg Phe Asn Ser Phe Tyr Arg Asp Gln Pro His Pro Phe Ile Thr	
	165 170 175	
	agt atg gtc cgt gca ctg gat gaa gca atg aac aag ctg cag cga gca	576
20	Ser Met Val Arg Ala Leu Asp Glu Ala Met Asn Lys Leu Gln Arg Ala	
	180 185 190	
	aat cca gac gac cca gct tat gat gaa aac aag cgc cag ttt caa gaa	624
	Asn Pro Asp Asp Pro Ala Tyr Asp Glu Asn Lys Arg Gln Phe Gln Glu	
	195 200 205	
25	gat atc aag gtg atg aac gac cta gta gat aaa att att gca gat cgc	672
	Asp Ile Lys Val Met Asn Asp Leu Val Asp Lys Ile Ile Ala Asp Arg	
	210 215 220	

-7-

	gga gac gat gtg gaa gag ttc cgt cca gag cgt ttt gaa aat cca agt	1152
	Gly Asp Asp Val Glu Glu Phe Arg Pro Glu Arg Phe Glu Asn Pro Ser	
	370 375 380	
5	gcg att ccg cag cat gcg ttt aaa ccg ttt gga aac ggt cag cgt gcg	1200
	Ala Ile Pro Gln His Ala Phe Lys Pro Phe Gly Asn Gly Gln Arg Ala	
	385 390 395 400	
	tgt atc ggt cag cag ttc gct ctt cat gaa gca acg ctg gta ctt ggt	1248
	Cys Ile Gly Gln Gln Phe Ala Leu His Glu Ala Thr Leu Val Leu Gly	
	405 410 415	
10	atg atg cta aaa cac ttt gac ttt gaa gat cat aca aac tac gag ctg	1296
	Met Met Leu Lys His Phe Asp Phe Glu Asp His Thr Asn Tyr Glu Leu	
	420 425 430	
	gat att aaa gaa act tta acg tta aaa cct gaa ggc ttt gtg gta aaa	1344
	Asp Ile Lys Glu Thr Leu Thr Leu Lys Pro Glu Gly Phe Val Val Lys	
15	435 440 445	
	gca aaa tcg aaa aaa att ccg ctt ggc ggt att cct tca cct agc act	1392
	Ala Lys Ser Lys Lys Ile Pro Leu Gly Gly Ile Pro Ser Pro Ser Thr	
	450 455 460	
20	gaa cag tct gcc aaa aaa gca cgc aaa aag gca gaa aac gct cat aat	1440
	Glu Gln Ser Ala Lys Lys Ala Arg Lys Lys Ala Glu Asn Ala His Asn	
	465 470 475 480	
	acg ccg ctg ctt gtg cta tac ggt tca aat atg gga aca gct gaa gga	1488
	Thr Pro Leu Leu Val Leu Tyr Gly Ser Asn Met Gly Thr Ala Glu Gly	
	485 490 495	
25	acg gcg cgt gat tta gca gat att gca atg agc aaa gga ttt gca ccg	1536
	Thr Ala Arg Asp Leu Ala Asp Ile Ala Met Ser Lys Gly Phe Ala Pro	
	500 505 510	

-8-

	cag gtc gca acg ctt gat tca cac gcc gga aat ctt ccg cgc gaa gga	1584
	Gln Val Ala Thr Leu Asp Ser His Ala Gly Asn Leu Pro Arg Glu Gly	
	515 520 525	
5	gct gta tta att gta acg gcg tct tat aac ggt cat ccg cct gat aac	1632
	Ala Val Leu Ile Val Thr Ala Ser Tyr Asn Gly His Pro Pro Asp Asn	
	530 535 540	
	gca aag caa ttt gtc gac tgg tta gac caa gcg tct gct gat gaa gta	1680
	Ala Lys Gln Phe Val Asp Trp Leu Asp Gln Ala Ser Ala Asp Glu Val	
	545 550 555 560	
10	aaa ggc gtt cgc tac tcc gta ttt gga tgc ggc gat aaa aac tgg gct	1728
	Lys Gly Val Arg Tyr Ser Val Phe Gly Cys Gly Asp Lys Asn Trp Ala	
	565 570 575	
	act acg tat caa aaa gtg cct gct ttt atc gat gaa acg ctt gcc gct	1776
	Thr Thr Tyr Gln Lys Val Pro Ala Phe Ile Asp Glu Thr Leu Ala Ala	
15	580 585 590	
	aaa ggg gca gaa aac atc gct gac cgc ggt gaa gca gat gca agc gac	1824
	Lys Gly Ala Glu Asn Ile Ala Asp Arg Gly Glu Ala Asp Ala Ser Asp	
	595 600 605	
	gac ttt gaa ggc aca tat gaa gaa tgg cgt gaa cat atg tgg agt gac	1872
20	Asp Phe Glu Gly Thr Tyr Glu Glu Trp Arg Glu His Met Trp Ser Asp	
	610 615 620	
	gta gca gcc tac ttt aac ctc gac att gaa aac agt gaa gat aat aaa	1920
	Val Ala Ala Tyr Phe Asn Leu Asp Ile Glu Asn Ser Glu Asp Asn Lys	
	625 630 635 640	
25	tct act ctt tca ctt caa ttt gtc gac agc gcc gcg gat atg ccg ctt	1968
	Ser Thr Leu Ser Leu Gln Phe Val Asp Ser Ala Ala Asp Met Pro Leu	
	645 650 655	

-9-

	gcg aaa atg cac ggt gcg ttt tca acg aac gtc gta gca agc aaa gaa	2016
	Ala Lys Met His Gly Ala Phe Ser Thr Asn Val Val Ala Ser Lys Glu	
	660 665 670	
5	ctt caa cag cca ggc agt gca cga agc acg cga cat ctt gaa att gaa	2064
	Leu Gln Gln Pro Gly Ser Ala Arg Ser Thr Arg His Leu Glu Ile Glu	
	675 680 685	
	ctt cca aaa gaa gct tct tat caa gaa gga gat cat tta ggt gtt att	2112
	Leu Pro Lys Glu Ala Ser Tyr Gln Glu Gly Asp His Leu Gly Val Ile	
	690 695 700	
10	cct cgc aac tat gaa gga ata gta aac cgt gta aca gca agg ttc ggc	2160
	Pro Arg Asn Tyr Glu Gly Ile Val Asn Arg Val Thr Ala Arg Phe Gly	
	705 710 715 720	
15	cta gat gca tca cag caa atc cgt ctg gaa gca gaa gaa gaa aaa tta	2208
	Leu Asp Ala Ser Gln Gln Ile Arg Leu Glu Ala Glu Glu Glu Lys Leu	
	725 730 735	
	gct cat ttg cca ctc gct aaa aca gta tcc gta gaa gag ctt ctg caa	2256
	Ala His Leu Pro Leu Ala Lys Thr Val Ser Val Glu Glu Leu Leu Gln	
	740 745 750	
20	tac gtg gag ctt caa gat cct gtt acg cgc acg cag ctt cgc gca atg	2304
	Tyr Val Glu Leu Gln Asp Pro Val Thr Arg Thr Gln Leu Arg Ala Met	
	755 760 765	
	gct gct aaa acg gtc tgc ccg ccg cat aaa gta gag ctt gaa gcc ttg	2352
	Ala Ala Lys Thr Val Cys Pro Pro His Lys Val Glu Leu Glu Ala Leu	
	770 775 780	
25	ctt gaa aag caa gcc tac aaa gaa caa gtg ctg gca aaa cgt tta aca	2400
	Leu Glu Lys Gln Ala Tyr Lys Glu Gln Val Leu Ala Lys Arg Leu Thr	
	785 790 795 800	

-10-

	atg ctt gaa ctg ctt gaa aaa tac ccg gcg tgt gaa atg aaa ttc agc	2448
	Met Leu Glu Leu Leu Glu Lys Tyr Pro Ala Cys Glu Met Lys Phe Ser	
	805 810 815	
5	gaa ttt atc gcc ctt ctg cca agc ata cgc ccg cgc tat tac tcg att	2496
	Glu Phe Ile Ala Leu Leu Pro Ser Ile Arg Pro Arg Tyr Tyr Ser Ile	
	820 825 830	
	tct tca tca cct cgt gtc gat gaa aaa caa gca agc atc acg gtc agc	2544
	Ser Ser Ser Pro Arg Val Asp Glu Lys Gln Ala Ser Ile Thr Val Ser	
	835 840 845	
10	gtt gtc tca gga gaa gcg tgg agc gga tat gga gaa tat aaa gga att	2592
	Val Val Ser Gly Glu Ala Trp Ser Gly Tyr Gly Glu Tyr Lys Gly Ile	
	850 855 860	
	gcg tcg aac tat ctt gcc gag ctg caa gaa gga gat acg att acg tgc	2640
	Ala Ser Asn Tyr Leu Ala Glu Leu Gln Glu Gly Asp Thr Ile Thr Cys	
15	865 870 875 880	
	ttt att tcc aca ccg cag tca gaa ttt acg ctg cca aaa gac cct gaa	2688
	Phe Ile Ser Thr Pro Gln Ser Glu Phe Thr Leu Pro Lys Asp Pro Glu	
	885 890 895	
	acg ccg ctt atc atg gtc gga ccg gga aca ggc gtc gcg ccg ttt aga	2736
20	Thr Pro Leu Ile Met Val Gly Pro Gly Thr Gly Val Ala Pro Phe Arg	
	900 905 910	
	ggc ttt gtg cag gcg cgc aaa cag cta aaa gaa caa gga cag tca ctt	2784
	Gly Phe Val Gln Ala Arg Lys Gln Leu Lys Glu Gln Gly Gln Ser Leu	
	915 920 925	
25	gga gaa gca cat tta tac ttc ggc tgc cgt tca cct cat gaa gac tat	2832
	Gly Glu Ala His Leu Tyr Phe Gly Cys Arg Ser Pro His Glu Asp Tyr	
	930 935 940	

-11-

	ctg tat caa gaa gag ctt gaa aac gcc caa agc gaa ggc atc att acg	2880
	Leu Tyr Gln Glu Glu Leu Glu Asn Ala Gln Ser Glu Gly Ile Ile Thr	
	945 950 955 960	
5	ctt cat acc gct ttt tct cgc atg cca aat cag ccg aaa aca tac gtt	2928
	Leu His Thr Ala Phe Ser Arg Met Pro Asn Gln Pro Lys Thr Tyr Val	
	965 970 975	
	cag cac gta atg gaa caa gac ggc aag aaa ttg att gaa ctt ctt gat	2976
	Gln His Val Met Glu Gln Asp Gly Lys Lys Leu Ile Glu Leu Leu Asp	
	980 985 990	
10	caa gga gcg cac ttc tat att tgc gga gac gga agc caa atg gca cct	3024
	Gln Gly Ala His Phe Tyr Ile Cys Gly Asp Gly Ser Gln Met Ala Pro	
	995 1000 1005	
	gcc gtt gaa gca acg ctt atg aaa agc tat gct gac gtt cac caa gtg	3072
	Ala Val Glu Ala Thr Leu Met Lys Ser Tyr Ala Asp Val His Gln Val	
15	1010 1015 1020	
	agt gaa gca gac gct cgc tta tgg ctg cag cag cta gaa gaa aaa ggc	3120
	Ser Glu Ala Asp Ala Arg Leu Trp Leu Gln Gln Leu Glu Glu Lys Gly	
	1025 1030 1035 1040	
	cga tac gca aaa gac gtg tgg gct ggg taa	3150
20	Arg Tyr Ala Lys Asp Val Trp Ala Gly	
	1045 1050	

INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 00/02379

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C12N15/53 C12P7/22 C12N9/02 A01K67/033 A01H5/00
A62D3/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12P C12N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

BIOSIS, EPO-Internal, EMBASE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 96 14419 A (BRITISH GAS PLC ; FLITSCH SABINE LAHJA (GB); NICKERSON DARREN PAUL) 17 May 1996 (1996-05-17) page 4, line 10 -page 8, line 15 page 31 claims	1-8, 11-15
X	SHIMOJI M ET AL: "DESIGN OF A NOVEL P450: A FUNCTIONAL BACTERIAL-HUMAN CYTOCHROME P450 CHIMERA" BIOCHEMISTRY, vol. 37, no. 25, 1998, pages 8848-8852, XP002913528 ISSN: 0006-2960 the whole document	1,4,6,7, 11-15,17

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

14 November 2000

Date of mailing of the international search report

28/11/2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Andres, S

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/GB 00/02379

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 97 16553 A (BRITISH GAS PLC ;WONG LUET LOK (GB); FLITSCH SABINE LAHJA (GB); NI) 9 May 1997 (1997-05-09) the whole document	1-5, 11-15
A	GOOCH, JAY W. ET AL: "Effects of ortho- and non-ortho-substituted polychlorinated biphenyl congeners on the hepatic monooxygenase system in scup (Stenotomus chrysops)" TOXICOL. APPL. PHARMACOL. (1989), 98(3), 422-33, XP000960619 the whole document	1,6-9
A	ENGLAND P A: "The oxidation of naphtalene and pyrene by cytochrome P450cam" FEBS LETTERS, vol. 424, no. 3, 13 March 1998 (1998-03-13), pages 271-274, XP002131695 ISSN: 0014-5793 the whole document	2-5
P,A	WO 00 31273 A (BELL STEPHEN GRAHAM ;CARMICHAEL ANGUS BISHOP (GB); WONG LUET LOK () 2 June 2000 (2000-06-02) page 3, line 23 -page 7, line 21 page 9, line 6 -page 17 examples claims	1-19
P,X	JONES, J. ET AL: "The oxidation of polychlorinated benzenes by genetically engineered cytochrome P450cam: potential applications in bioremediation" CHEM. COMMUN. (CAMBRIDGE), no. 3, 7 February 2000 (2000-02-07), pages 247-248, XP002152716 the whole document	1-10, 17-19

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/GB 00/02379

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9614419 A	17-05-1996	AU 705736 B	03-06-1999
		AU 3811795 A	31-05-1996
		CN 1171818 A	28-01-1998
		CZ 9701277 A	15-10-1997
		EP 0789770 A	20-08-1997
		GB 2294692 A, B	08-05-1996
		JP 10503658 T	07-04-1998
		KR 234348 B	15-12-1999
		NZ 294904 A	24-09-1998
		PL 319970 A	01-09-1997
		RU 2133774 C	27-07-1999
		SK 54597 A	04-02-1998
		US 6100074 A	08-08-2000
WO 9716553 A	09-05-1997	AU 716583 B	02-03-2000
		AU 7323696 A	22-05-1997
		CA 2236381 A	09-05-1997
		CN 1212015 A	24-03-1999
		CZ 9801273 A	13-01-1999
		EP 0906431 A	07-04-1999
		GB 2306485 A, B	07-05-1997
		JP 2000508163 T	04-07-2000
		NZ 320497 A	29-09-1999
		PL 326445 A	28-09-1998
		SK 55598 A	13-04-1999
		US 6117661 A	12-09-2000
		AU 705736 B	03-06-1999
		AU 3811795 A	31-05-1996
		CZ 9701277 A	15-10-1997
		EP 0789770 A	20-08-1997
		JP 10503658 T	07-04-1998
		KR 234348 B	15-12-1999
		NZ 294904 A	24-09-1998
		PL 319970 A	01-09-1997
		RU 2133774 C	27-07-1999
		SK 54597 A	04-02-1998
		US 6100074 A	08-08-2000
WO 0031273 A	02-06-2000	AU 1281900 A	13-06-2000

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

14



(PCT Article 36 and Rule 70)

Applicant's or agent's file reference N.76277A PEJ		FOR FURTHER ACTION See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416)	
International application No. PCT/GB00/02379	International filing date (day/month/year) 19/06/2000	Priority date (day/month/year) 18/06/1999	
International Patent Classification (IPC) or national classification and IPC C12N15/53			
Applicant ISIS INNOVATION LIMITED			

1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.
2. This REPORT consists of a total of 6 sheets, including this cover sheet.
 - ☒ This report is also accompanied by ANNEXES, i.e. sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).

These annexes consist of a total of 2 sheets.

3. This report contains indications relating to the following items:
 - I ☒ Basis of the report
 - II ☐ Priority
 - III ☐ Non-establishment of opinion with regard to novelty, inventive step and industrial applicability
 - IV ☐ Lack of unity of invention
 - V ☒ Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
 - VI ☐ Certain documents cited
 - VII ☐ Certain defects in the international application
 - VIII ☒ Certain observations on the international application

Date of submission of the demand 15/01/2001	Date of completion of this report 21.09.2001
Name and mailing address of the international preliminary examining authority:  European Patent Office D-80298 Munich Tel. +49 89 2399 - 0 Tx: 523656 epmu d Fax: +49 89 2399 - 4465	Authorized officer Stoyanov, B Telephone No. +49 89 2399 7726 

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No. PCT/GB00/02379

I. Basis of the report

1. With regard to the **elements** of the international application (*Replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to this report since they do not contain amendments (Rules 70.16 and 70.17)*):

Description, pages:

1-25 as originally filed

Claims, No.:

1-18 as received on 21/08/2001 with letter of 20/08/2001

Claims, pages:

26,27 as received on 21/08/2001 with letter of 20/08/2001

2. With regard to the **language**, all the elements marked above were available or furnished to this Authority in the language in which the international application was filed, unless otherwise indicated under this item.

These elements were available or furnished to this Authority in the following language: , which is:

- ☐ the language of a translation furnished for the purposes of the international search (under Rule 23.1(b)).
- ☐ the language of publication of the international application (under Rule 48.3(b)).
- ☐ the language of a translation furnished for the purposes of international preliminary examination (under Rule 55.2 and/or 55.3).
3. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international preliminary examination was carried out on the basis of the sequence listing:
- ☐ contained in the international application in written form.
- ☐ filed together with the international application in computer readable form.
- ☐ furnished subsequently to this Authority in written form.
- ☐ furnished subsequently to this Authority in computer readable form.
- ☐ The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.
- ☐ The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.
4. The amendments have resulted in the cancellation of:
- ☐ the description, pages:
- ☒ the claims, Nos.: 1-19

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No. PCT/GB00/02379

☐ the drawings, sheets:

5. ☐ This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed (Rule 70.2(c)):

(Any replacement sheet containing such amendments must be referred to under item 1 and annexed to this report.)

6. Additional observations, if necessary:

V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. Statement

Novelty (N)	Yes:	Claims	1-13, 15-18
	No:	Claims	14

Inventive step (IS)	Yes:	Claims	none
	No:	Claims	1-18

Industrial applicability (IA)	Yes:	Claims	1-18
	No:	Claims	

2. Citations and explanations
see separate sheet

VIII. Certain observations on the international application

The following observations on the clarity of the claims, description, and drawings or on the question whether the claims are fully supported by the description, are made:

see separate sheet

This IPER is based on the following prior art documents:

D1:

SHIMOJI M ET AL: 'DESIGN OF A NOVEL P450: A FUNCTIONAL BACTERIAL-HUMAN CYTOCHROME P450 CHIMERA' BIOCHEMISTRY, vol. 37, no. 25, 1998, pages 8848-8852, XP002913528 ISSN: 0006-2960

D2:

WO 96 14419 A (BRITISH GAS PLC ;FLITSCH SABINE LAHJA (GB); NICKERSON DARREN PAUL) 17 May 1996 (1996-05-17)

Section V

Claim 14 of present application cannot be considered novel since the features defined in said claim may be inherent property of naturally occurring *Pseudomonas putida*. Hence, claim 14 is in discordance to **Article 33(2) PCT**.

Closest prior art to the subject matter of claims 1 - 9 is regarded as being D2.

The problem to be solved can be seen in the provision of a method to oxidise specific halo aromatic compounds on a ring carbon atom.

This problem could be solved by using the properties of the wild type and of active site mutants of P450cam to oxidise such compounds.

The subject matter of claims 1 - 9 differs from D2 in that said P450cam and active site mutants thereof are used in a process for oxidation of 1,2-dichlorobenzene, 1,2,4-trichlorobenzene, 3,3'-dichlorobiphenyl, 2,2',4,5,5'-pentachlorobiphenyl, pentachlorobenzene or hexachlorobenzene.

However, the definition of new substrates for a known enzyme cannot be considered to fulfill the requirements of **Article 33 (3) PCT** for the following reasons:

1.

D2 already discloses a method to oxidise condensed aromatic compounds, such as naphthalene, phenanthrene, fluoranthrene and pyrene where the oxidised carbon is a **ring carbon** of the substrate (see for instance Figures 4 c-f).

2.

D2 also suggests a method for oxidising halo aromatic compounds (e.g. diphenyl and biphenyl compounds and their halogenated variants, see for instance page 4, lines 10-27 and claim 5) using mutants in the active site of the *P. putida*'s mono-oxygenase P450cam, where said mutants include among others a Y96A mutant (see e.g. page 6 first paragraph, page 8 last paragraph, claim 7 and Fig.1). D2 also teaches how to modify the active site of the wild type enzyme in order to decrease its specificity towards camphor, creating a desired "aromatic pocket" (see e.g. pages 3 and 4) and that the amino acid which replaces Y96 is conveniently a small hydrophobic amino acid (for instance a non-polar one) like Ala, Gly, Val, Leu or Ile.

Thus, in view of D2 the elucidation of further mono-oxygenase substrates chemically closely related to known ones is obvious to somebody skilled in the art.

In view of D2 the subject matter of claims **10, 11, 13 and 18** is obvious to the skilled artisan, contrary to the requirements of **Article 33(3) PCT**.

The subject matter of claim **12** of present international application cannot be considered to fulfill the requirements of **Article 33 (3) PCT**, since expression of known exogenous genes in prokaryotic/eucaryotic cells with the aim to conduct a biochemical process in said cells is obvious to the person skilled in the art.

Claim **15** does not fulfill the requirements of **Article 33 (3) PCT**, since the use of known genes (see e.g. D2, pages 3-6) to create transgenic animals or plants merely can be seen as routine methods.

Document D1 suggests that modified P450 enzymes can be used for bioremediation of areas polluted with halo aromatic compounds (see e.g. abstract and page 8852). Hence, subject matter of claim **16** is in discordance to **Article 33 (3) PCT**.

Claim **17** does not fulfill the requirements of **Article 33(3) PCT** since a process for the selection of mutants of a known enzyme with well documented and chemically related substrates is seen as being a routine method for somebody skilled in the art.

Section VIII

**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT - SEPARATE SHEET**

International application No. PCT/GB00/02379

1)

The numbering of claim 19 of new set of claims filed with the letter of 20 August 2001 is considered a typing error and is referred to in this report as claim 18.

2)

Applicants attention is drawn to the fact that in the absence of a reference point terms like "less polar" and "homologue" are meaningless. Thus, claims containing at least one of the above mentioned expressions are unclear and does not meet the requirements of **Article 6 PCT**.

3)

It is highly questionable that any fragment of the putidaredoxin reductase and/or putidaredoxin are actually suitable for the process according to claim **11** since in its broadest meaning the term "fragment" cover individual amino acids (**Article 5 and 6 PCT**).

CLAIMS

1. Process for oxidising a halo aromatic substrate which has more than one halogen atom, which process comprises oxidising said substrate with a monooxygenase enzyme, wherein a ring carbon of the substrate is oxidised.
2. Process according to claim 1 in which the enzyme comprises a substitution of an amino acid in the active site by an amino acid with a less polar side-chain.
3. Process according to claim 2 in which the enzyme comprises one or more other amino acid substitutions in the active site.
4. Process according to any one of the preceding claims in which the enzyme is:
 - (i) P450_{cam}, or
 - (ii) a naturally occurring homologue of (i), or
 - (iii) a mutant of (i) or (ii).
5. Process according to claim 4 in which the enzyme is one in which amino acid 96 of P450_{cam}, or the equivalent amino acid in a homologue, has been changed to an amino acid with a less polar side-chain.
6. Process according to any one of the preceding claims in which the halogen is chlorine.
7. Process according to any one of the preceding claims in which the aromatic compound is a benzene or biphenyl.
8. Process for oxidising a halo aromatic substrate, which process comprises oxidising said substrate with an enzyme as defined in any one of claims 1 to 5, wherein the substrate is 1, 2-dichlorobenzene, 1, 2, 4-trichlorobenzene, 3,3'-dichlorobiphenyl or 2,2',4,5,5'-pentachlorobiphenyl.
9. Process for oxidising a halo aromatic substrate, which process comprises oxidising said substrate with an enzyme as defined in any one of claims 1 to 5, wherein the substrate is pentachlorobenzene or hexachlorobenzene.
10. Process according to any one of the preceding claims which is carried out in a cell that expresses:
 - (a) an enzyme as defined in any one of claims 1 to 5;
 - (b) an electron transfer reductase; and
 - (c) an electron transfer redoxin.

11. Process according to claim 10 in which:
- (b) is putidaretoxin reductase or a homologue; or a fragment thereof; and/or
 - (c) is putidaretoxin or a homologue; or a fragment thereof.
12. Process according to claim 10 or 11 wherein the cell is one in which the enzyme (a) does not naturally occur.
13. Process according to any one of claims 10 to 12 wherein the cell is one which in its naturally occurring form is able to oxidise a substrate as defined in any one of claims 6 to 9.
14. A cell as defined in claim 13.
15. A transgenic animal or plant whose cells are as defined in any one of claims 10 to 13.
16. Method of treating a locus contaminated with a substrate as defined in any one of claims 1 or 6 to 9 comprising contacting the locus with an enzyme as defined in any one of claims 1 to 5 or a cell as defined in any of claims 10 to 12, or an animal or plant as defined in claim 15.
17. Process for selecting a mutant of an enzyme as defined in claim 1, 4(i) or 4(ii) for its ability to oxidise a substrate as defined in claim 1, or any one of the claims 6 to 9, which process comprises screening a library of said mutants for their oxidation effect on the substrate.
- ~~18~~ 18. Process, cell, animal, plant or method according to any one of claims 1 to 16 wherein the enzyme is one that has been selected in a process according to claim 17.

PCT

INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference N.76277A PEJ	FOR FURTHER ACTION see Notification of Transmittal of International Search Report (Form PCT/ISA/220) as well as, where applicable, item 5 below.	
International application No. PCT/GB 00/ 02379	International filing date (day/month/year) 19/06/2000	(Earliest) Priority Date (day/month/year) 18/06/1999
Applicant ISIS INNOVATION LIMITED		

This International Search Report has been prepared by this International Searching Authority and is transmitted to the applicant according to Article 18. A copy is being transmitted to the International Bureau.

This International Search Report consists of a total of 3 sheets.

☒ It is also accompanied by a copy of each prior art document cited in this report.

1. Basis of the report

a. With regard to the **language**, the international search was carried out on the basis of the international application in the language in which it was filed, unless otherwise indicated under this item.

☐ the international search was carried out on the basis of a translation of the international application furnished to this Authority (Rule 23.1(b)).

b. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international search was carried out on the basis of the sequence listing :

☒ contained in the international application in written form.

☐ filed together with the international application in computer readable form.

☐ furnished subsequently to this Authority in written form.

☒ furnished subsequently to this Authority in computer readable form.

☐ the statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.

☒ the statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished

2. ☐ **Certain claims were found unsearchable** (See Box I).

3. ☐ **Unity of invention is lacking** (see Box II).

4. With regard to the **title**,

☒ the text is approved as submitted by the applicant.

☐ the text has been established by this Authority to read as follows:

5. With regard to the **abstract**,

☒ the text is approved as submitted by the applicant.

☐ the text has been established, according to Rule 38.2(b), by this Authority as it appears in Box III. The applicant may, within one month from the date of mailing of this international search report, submit comments to this Authority.

6. The figure of the **drawings** to be published with the abstract is Figure No.

☐ as suggested by the applicant.

☐ because the applicant failed to suggest a figure.

☐ because this figure better characterizes the invention.

☒ None of the figures.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/JP 00/02379

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C12N15/53 C12P7/22 C12N9/02 A01K67/033 A01H5/00
A62D3/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12P C12N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

BIOSIS, EPO-Internal, EMBASE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 96 14419 A (BRITISH GAS PLC ;FLITSCH SABINE LAHJA (GB); NICKERSON DARREN PAUL) 17 May 1996 (1996-05-17) page 4, line 10 -page 8, line 15 page 31 claims	1-8, 11-15
X	SHIMOJI M ET AL: "DESIGN OF A NOVEL P450: A FUNCTIONAL BACTERIAL-HUMAN CYTOCHROME P450 CHIMERA" BIOCHEMISTRY, vol. 37, no. 25, 1998, pages 8848-8852, XP002913528 ISSN: 0006-2960 the whole document	1,4,6,7, 11-15,17



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents :

A document defining the general state of the art which is not considered to be of particular relevance

E earlier document but published on or after the international filing date

L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

O document referring to an oral disclosure, use, exhibition or other means

P document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

& document member of the same patent family

Date of the actual completion of the international search

14 November 2000

Date of mailing of the international search report

28/11/2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Andres, S

INTERNATIONAL SEARCH REPORT

International Application No

PCT/ 00/02379

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 97 16553 A (BRITISH GAS PLC ;WONG LUET LOK (GB); FLITSCH SABINE LAHJA (GB); NI) 9 May 1997 (1997-05-09) the whole document ---	1-5, 11-15
A	GOOCH, JAY W. ET AL: "Effects of ortho- and non-ortho-substituted polychlorinated biphenyl congeners on the hepatic monooxygenase system in scup (Stenotomus chrysops)" TOXICOL. APPL. PHARMACOL. (1989), 98(3), 422-33 , XP000960619 the whole document ---	1,6-9
A	ENGLAND P A: "The oxidation of naphtalene and pyrene by cytochrome P450cam" FEBS LETTERS, vol. 424, no. 3, 13 March 1998 (1998-03-13), pages 271-274, XP002131695 ISSN: 0014-5793 the whole document ---	2-5
P,A	WO 00 31273 A (BELL STEPHEN GRAHAM ;CARMICHAEL ANGUS BISHOP (GB); WONG LUET LOK () 2 June 2000 (2000-06-02) page 3, line 23 -page 7, line 21 page 9, line 6 -page 17 examples claims ---	1-19
P,X	JONES, J. ET AL: "The oxidation of polychlorinated benzenes by genetically engineered cytochrome P450cam: potential applications in bioremediation" CHEM. COMMUN. (CAMBRIDGE) , no. 3, 7 February 2000 (2000-02-07), pages 247-248, XP002152716 the whole document -----	1-10, 17-19

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/JP00/02379

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9614419	A	17-05-1996	AU 705736 B	03-06-1999
			AU 3811795 A	31-05-1996
			CN 1171818 A	28-01-1998
			CZ 9701277 A	15-10-1997
			EP 0789770 A	20-08-1997
			GB 2294692 A, B	08-05-1996
			JP 10503658 T	07-04-1998
			KR 234348 B	15-12-1999
			NZ 294904 A	24-09-1998
			PL 319970 A	01-09-1997
			RU 2133774 C	27-07-1999
			SK 54597 A	04-02-1998
			US 6100074 A	08-08-2000
WO 9716553	A	09-05-1997	AU 716583 B	02-03-2000
			AU 7323696 A	22-05-1997
			CA 2236381 A	09-05-1997
			CN 1212015 A	24-03-1999
			CZ 9801273 A	13-01-1999
			EP 0906431 A	07-04-1999
			GB 2306485 A, B	07-05-1997
			JP 2000508163 T	04-07-2000
			NZ 320497 A	29-09-1999
			PL 326445 A	28-09-1998
			SK 55598 A	13-04-1999
			US 6117661 A	12-09-2000
			AU 705736 B	03-06-1999
			AU 3811795 A	31-05-1996
			CZ 9701277 A	15-10-1997
			EP 0789770 A	20-08-1997
			JP 10503658 T	07-04-1998
			KR 234348 B	15-12-1999
			NZ 294904 A	24-09-1998
			PL 319970 A	01-09-1997
			RU 2133774 C	27-07-1999
			SK 54597 A	04-02-1998
			US 6100074 A	08-08-2000
WO 0031273	A	02-06-2000	AU 1281900 A	13-06-2000